Literature DB >> 8959763

C-type natriuretic peptide.

C S Barr1, P Rhodes, A D Struthers.   

Abstract

C-type natriuretic peptide is a 22-amino acid peptide that was initially identified in the central nervous system. The distribution of C-type natriuretic peptide, which has structural homology with atrial and brain natriuretic peptides, is wide and includes the endothelium, myocardium, gastrointestinal, and genitourinary tracts. The biological effects of this peptide are being elucidated in a number of sites in a number of species; however, the novel endothelial site of production of C-type natriuretic peptide and the proximal situation of its receptor in vascular smooth muscle suggest that this vascular natriuretic peptide system may play a role in concert with other local systems in the control of vascular tone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8959763     DOI: 10.1016/s0196-9781(96)00110-6

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  22 in total

1.  Intracerebroventricular administration of atrial natriuretic peptide prevents increase of plasma ADH, aldosterone and corticosterone levels in restrained conscious dehydrated rabbits.

Authors:  C Kallaras; N Angelopoulos; S Bountzioukas; K Mavroudis; M Karamouzis; O Guiba-Tziampiri
Journal:  J Endocrinol Invest       Date:  2004-10       Impact factor: 4.256

2.  In vivo Evaluation of Cenderitide-Eluting Stent (CES) II.

Authors:  Yingying Huang; Xu Wen Ng; Soon Ghim Lim; Horng Haur Chen; John C Burnett; Yin Chiang Freddy Boey; Subbu S Venkatraman
Journal:  Ann Biomed Eng       Date:  2015-07-16       Impact factor: 3.934

3.  C-type natriuretic peptide modulates permeability of the blood-brain barrier.

Authors:  Manoj Bohara; Yuki Kambe; Tetsuya Nagayama; Hiroshi Tokimura; Kazunori Arita; Atsuro Miyata
Journal:  J Cereb Blood Flow Metab       Date:  2014-01-08       Impact factor: 6.200

Review 4.  Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia.

Authors:  Jia Chen; Jiaqi Liu; Yangzhong Zhou; Sen Liu; Gang Liu; Yuzhi Zuo; Zhihong Wu; Nan Wu; Guixing Qiu
Journal:  J Mol Med (Berl)       Date:  2017-10-23       Impact factor: 4.599

5.  Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial natriuretic peptide.

Authors:  M F Goy; P M Oliver; K E Purdy; J W Knowles; J E Fox; P J Mohler; X Qian; O Smithies; N Maeda
Journal:  Biochem J       Date:  2001-09-01       Impact factor: 3.857

6.  In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator.

Authors:  Jeffrey D Edelson; Marie Makhlina; Kevin R Silvester; Shailesh S Vengurlekar; Xiaomei Chen; Jie Zhang; Cynthia J Koziol-White; Philip R Cooper; Trevor J Hallam; Douglas W P Hay; Reynold A Panettieri
Journal:  Pulm Pharmacol Ther       Date:  2012-11-12       Impact factor: 3.410

Review 7.  Urodilatin: a better natriuretic peptide?

Authors:  David L Vesely
Journal:  Curr Heart Fail Rep       Date:  2007-09

8.  Pacemaker currents modulated by C-type natriuretic peptide in interstitial cells of cajal from murine small intestine.

Authors:  Y Zhang; L Hua Piao; X Huang; Y Fei Han; P Zhao; L Gao; Y Kim; W X Xu
Journal:  J Physiol Biochem       Date:  2006-12       Impact factor: 4.158

9.  Regulation of axonal development by natriuretic peptide hormones.

Authors:  Zhen Zhao; Le Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-01       Impact factor: 11.205

10.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.